Blotta et al. suggested that the simultaneous use of GLI- and SMO-inhibitors serve as a more potent combination therapy in multiple myeloma for inhibiting the HH signaling cascade at multiple interfaces [43]. The gene discussed is GLI1; the disease is plasma cell myeloma.